A nice presentation. Actually found out a couple things that didn't know about FSGS. Didn't recall Encysive ran a Phase 2 study in that indication. Said it reduced Proteinuria I believe 40%. (It should be noted Encysive's drug was pulled by Pfizer for safety)
Still think its a risky company and the lead indication has too many risks for me (safety, why Gilead/GSK don't try, etc.). Overall though a very nice presentation and I wish them luck (I still have a little Ligand and hope to reacquire more after people realize Promacta is a nice drug but not a 1B+ drug)
Market Data 
Markets 
AI
